448 related articles for article (PubMed ID: 24210543)
21. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
22. High TBX2 expression predicts poor prognosis in non-small cell lung cancer.
Zhang Z; Guo Y
Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744
[TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
Cox G; Jones JL; O'Byrne KJ
Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
[TBL] [Abstract][Full Text] [Related]
24. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer.
Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH
J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
26. HSPA2 is expressed in human tumors and correlates with clinical features in non-small cell lung carcinoma patients.
Scieglinska D; Gogler-Piglowska A; Butkiewicz D; Chekan M; Malusecka E; Harasim J; Habryka A; Krawczyk Z
Anticancer Res; 2014 Jun; 34(6):2833-40. PubMed ID: 24922646
[TBL] [Abstract][Full Text] [Related]
27. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
28. Expression of epidermal growth factor receptor in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Choi IS; Wang H; Resetkova E; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Albarracin CT
Cancer; 2007 Feb; 109(4):658-67. PubMed ID: 17211865
[TBL] [Abstract][Full Text] [Related]
29. L-type amino acid transporter 1 expression is a prognostic marker in patients with surgically resected stage I non-small cell lung cancer.
Imai H; Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Kanai Y; Endou H; Nakajima T; Mori M
Histopathology; 2009 Jun; 54(7):804-13. PubMed ID: 19635099
[TBL] [Abstract][Full Text] [Related]
30. Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer.
Leinonen T; Pirinen R; Böhm J; Johansson R; Rinne A; Weber E; Kosma VM
J Clin Pathol; 2007 May; 60(5):515-9. PubMed ID: 16790691
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients.
Al-Saad S; Al-Shibli K; Donnem T; Andersen S; Bremnes RM; Busund LT
J Thorac Oncol; 2010 Oct; 5(10):1536-43. PubMed ID: 20802349
[TBL] [Abstract][Full Text] [Related]
32. Expression of maspin in non-small-cell lung cancer: correlation with clinical features.
Takanami I; Abiko T; Koizumi S
Clin Lung Cancer; 2008 Nov; 9(6):361-6. PubMed ID: 19073519
[TBL] [Abstract][Full Text] [Related]
33. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Okuma Y; Hosomi Y; Nagamata M; Yamada Y; Sekihara K; Kato K; Hishima T; Okamura T
Anticancer Res; 2013 Nov; 33(11):5057-64. PubMed ID: 24222150
[TBL] [Abstract][Full Text] [Related]
35. Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer.
Iwasaki T; Nakagawa K; Nakamura H; Takada Y; Matsui K; Kawahara K
Oncol Rep; 2005 Jun; 13(6):1075-80. PubMed ID: 15870924
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of thyroid transcription factor-1 in primary, resected, non-small cell lung carcinoma.
Puglisi F; Barbone F; Damante G; Bruckbauer M; Di Lauro V; Beltrami CA; Di Loreto C
Mod Pathol; 1999 Mar; 12(3):318-24. PubMed ID: 10102618
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer.
Reinmuth N; Kloos S; Warth A; Risch A; Muley T; Hoffmann H; Thomas M; Meister M
Hum Pathol; 2014 Jun; 45(6):1162-8. PubMed ID: 24745618
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Koyama N; Uchida Y
Anticancer Res; 2013 Nov; 33(11):5083-9. PubMed ID: 24222153
[TBL] [Abstract][Full Text] [Related]
39. Differences in metabolism between adeno- and squamous cell non-small cell lung carcinomas: spatial distribution and prognostic value of GLUT1 and MCT4.
Meijer TW; Schuurbiers OC; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; Verhagen AF; Lok J; van der Heijden HF; Rademakers SE; Span PN; Bussink J
Lung Cancer; 2012 Jun; 76(3):316-23. PubMed ID: 22153830
[TBL] [Abstract][Full Text] [Related]
40. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
